Peyronie's disease (PD) is an acquired fibrotic condition of the tunica albuginea that is characterized by penile curvature, deformity, pain, and impaired sexual function. PD is prevalent among all ...

The 2026 PSMA & Beyond conference featured a session on challenges of radioligand therapy and a presentation by Dr. Inès Camille Azrour discussing renal toxicity associated with PSMA targeted therapy.

The 2026 PSMA & Beyond conference featured a challenges of radioligand therapy session and a presentation by Dr. Daniel Childs discussing long term marrow toxicity rates and risk factors. 177 ...

The 2026 PSMA & Beyond conference featured a session on challenges of radioligand therapy and a presentation by Dr. Michael Hofman discussing the expansion of the theranostic dream. Only 8 years ago, ...

Dr. Morris then discussed the PCWG4 Rule of 5 for defining radiographic progression free survival in the post-flare period. If there are <=5 new metastases, a confirmatory scan is performed, and if ...

The 2026 PSMA & Beyond conference featured a developing novel radioligands session and presentation by Dr. Philipp Backhaus discussing the initial experience with APC3. The history of ACP3 goes back ...

The 2026 PSMA & Beyond conference featured a clinical development session and presentation by Dr. William Maguire discussing regulatory considerations related to PSMA PET imaging in clinical trials.

The 2026 PSMA & Beyond conference featured a developing novel radioligands session and presentation by Dr. Wolfgang Fendler discussing the pro stance for the future of FAP. Fibroblast Activation ...

The trial design for ARASTEP is highlighted in the following schema: Two special considerations for ARASTEP are that all patients have maximally treated pelvic disease and that metastasis directed ...

The 2026 PSMA & Beyond conference featured a developing novel radioligands session and presentation by Dr. Lena Unterrainer discussing the con stance for the future of FAP. The primary challenge with ...

The 2026 PSMA & Beyond conference featured a targeting the cell surface session and presentation by Dr. Rahul Aggarwal discussing DLL3 and whether target expression determines the method of targeting.

The 2026 PSMA & Beyond conference featured a targeting the cell surface session and presentation by Dr. Tanya Dorff discussing antibody drug conjugates and BiTEs and their role in prostate cancer. Dr.